NextCure Inc - Asset Resilience Ratio
NextCure Inc (NXTC) has an Asset Resilience Ratio of 21.34% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NXTC working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how NextCure Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is NextCure Inc's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down NextCure Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of NextCure Inc for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.83 Million | 21.34% |
| Total Liquid Assets | $4.83 Million | 21.34% |
Asset Resilience Insights
- Good Liquidity Position: NextCure Inc maintains a healthy 21.34% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
NextCure Inc Industry Peers by Asset Resilience Ratio
Compare NextCure Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for NextCure Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for NextCure Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 31.56% | $15.84 Million | $50.18 Million | -19.02pp |
| 2024-12-31 | 50.57% | $40.89 Million | $80.86 Million | -23.79pp |
| 2023-12-31 | 74.37% | $95.22 Million | $128.04 Million | +1.99pp |
| 2022-12-31 | 72.37% | $133.28 Million | $184.16 Million | -13.13pp |
| 2021-12-31 | 85.51% | $207.25 Million | $242.39 Million | +3.76pp |
| 2020-12-31 | 81.75% | $250.68 Million | $306.64 Million | -2.63pp |
| 2019-12-31 | 84.37% | $300.51 Million | $356.17 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $147.63 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $19.47 Million | -- |
About NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leuke… Read more